Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MASTERS-2: MultiStem in Acute Ischemic Stroke
NCT03545607Phase 3Terminated
- Sponsor
- Healios
- Start
- Jul 2018
- Primary completion
- Oct 2024
- Modality
- Stem Cell Therapies
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in ischemic stroke comparing MultiStem with Placebo (2 arms). Primary endpoint: modified Rankin Scale Shift Analysis at 90 days. Started Jul 2018; status: terminated.
02
Drugs
invimestrocel
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT03545607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03545607.